Brief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
04/03/2024 15:24
March 4 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTS FOR
REVIEW
THE MARKETING AUTHORIZATION APPLICATION FOR SELADELPAR FOR THE
TREATMENT OF PRIMARY BILIARY CHOLANGITIS
Source text for Eikon: ID:nGNX5l38tk
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap